1. Introduction {#sec1-1}
===============

The GI Cancers are one of the most common cancers and cause of the cancer death in Asia and most developing countries such as Iran ([@ref12]; [@ref30]; [@ref31]). Generally, gastrointestinal malignancies are mainly occurring in stomach, esophagus and colorectal and are comprising more than 38% of all cancers and approximately accounting for more than half of the cancer mortality in Iran. Cancers of stomach, esophagus, and breast, prostate and colorectal after the skin cancer are the five common cancers in both sexes in Iran ([@ref28]).

Mortality rate of Gastrointestinal Cancers is more than the other cancers ([@ref30]). The esophageal cancer is the 8^th^ commonest cause of death globally with short survival rate of about 40% after one year of diagnosis. Total 5-year survival rate of esophageal cancer is estimated at 12% in Iran. Gastric cancer is the 4^th^ most common cause of death globally and its overall 5-year survival rate is less than 20% while colorectal cancer is the 5^th^ commonest oneand its incidence rate is stable or increasing in most countries. Overall 5-year survival rate of colorectal cancer was about 41% in Iran, and its proportion in people younger than 40 was more than those seen in western countries ([@ref32]; [@ref45]; [@ref8]).

The cause of gastrointestinal cancers is yet unknown and the role of genetic and environmental factors in their etiology vary according to each organ involved and also in their subtypes to the extent that the role of genetic factor is uncertain in esophageal cancer although its familial aggregations is reported from china ([@ref7]; [@ref20]), Sweden and America ([@ref13]; [@ref17]). In contrast the role of genetic factor is definite in FAP (familial adenomatous polyposis) contributing to less than 1% of colonic cancers to the extend that this autosomal dominant disease can be diagnosed in the carrier of this gene and cancer can be prevented by appropriate screening while non-carriers are safe ([@ref38]; [@ref6]). The MMR (mismatched DNA repair) gene is between of above two in such a way that this gene can be also found in 15% of sporadic colonic cancer ([@ref16]) while there are cases of lynch syndrome contributing to 3 to 5% of colonic cancers that are devoid of this gene. If this gene is found in appropriate clinical setting its application is as same as that of APC (adenomatous polyposis coli) gene in FAP. In the subtype of hereditary diffuse gastric cancergermline mutations of the CDH1 gene inherited as an autosomal dominant patternif detected ([@ref9]) has the same application as that of MMR as thismutation can also be found in sporadic gastric cancer ([@ref14]). Role of genetic is also clear in the prognostication of colon cancer as detection of microsatellite instability indicates a more favorable outcome ([@ref29]). CEA (CarcinoEmbryogenic antigen) as a tumor marker is also used in colon cancer initially at diagnosis and for follow up to detect metastasis ([@ref35]). Regarding the role of environmental factors, as for example the low oral hygiene ([@ref21]) and N-nitroso compounds are well known in esophageal and gastric cancer ([@ref42]; [@ref15]) to the extent that an esophageal belt cancer is found (Iran being part of it) and same is also true in gastric cancer to the extent that its endemic areas are known (Iran being part of it). Although the colon cancer was previously found to be more common in western countries because of their life style and high fat diet ([@ref4]) but its prevalence is also rising in Middle East countries to the extent that nowadays its incidence in patients younger than 40 year is 15-35percentagainst 2-8percentseen in western countries ([@ref8]). So far as the treatment is considered endoscopic treatment is used both in early stage ([@ref40]) of these cancers and also as palliative in their advanced stages ([@ref43]). Surgery is mostly needed in them with or without chemo±radio therapy as neoadjuvant and adjuvant treatment or as the only treatment. Other cancers of this system are not reported in our cases because of being very few and therefore no discussion is made.

In the recent decades survival of patients with gastrointestinal cancer has increased by using surgical and nonsurgical methods but their overall survival has not changed. Generally as the gastrointestinal malignancies remain asymptomatic until they reach to an advanced stage therefore this delay in diagnosis results in their short survival ([@ref33]). In studies related to the survival rate of gastrointestinal malignancies different considerations including their demographics (age, sex, education, income and etc), social individual and therapeutic modalities, are mentioned to be as important measures affecting the survival rate of these patients. The aim of this study is to determine the effective factors on survival of patients with gastrointestinal cancers with respect to their demographic characteristics, type of cancer, type of treatment, stage of disease, location of tumor and morphology and is also to estimate their survival rate during a 5-years of follow up according to the type of gastrointestinal cancers.

2. Methods {#sec1-2}
==========

This is a prospective study is conducted at Rahimian charity hospital (the only center of endoscopy) of Alvand city in Qazvin province. A total of 157 patients diagnosed as cancers of esophagus, stomach and colorectum based on the pathology report from 2007 to 2009 were included in this study and followed for five years. Survival status of patients was pursued by telephone contact with their relatives and also via the personal status registration organization of Qazvin province. Survival rate is calculated as per month. The effect of demographic variables including gender, age, income level, educational level, ethnicity (based on the ethnic groups studied in most studies in Iran), smoking, type of cancer, Location of tumor, morphology, stage of disease and also type of treatment including surgery only, CT and or RT (Chemotherapy/Radiotherapy) and combination therapy (Surgery and adjuvant or neoadjuvant therapy) was evaluated on the patients survival. The univariate analysis with Kaplan-Meier method and also the Cox model was used for the estimation of survival rate and determination of effective factors on it. Analysis of data was done at significant level of 0.05 by SPSS 16.

3. Results {#sec1-3}
==========

In this study of a total of 157 patients suffering from gastrointestinal cancers, the survival observations of 146 patients was analyzed of whom99 were males (67.8%) and 47 were females (32.2%). The mean age of patients at the time of diagnosis was 64.73± 13.23 and 58.28±13.91 for females and males respectively. Out of the total of patients studied, 58.9% died during the study of whom 30.2% were females and 69.8% were males and 41% were still alive who were considered as of censored. The proportions of different type of gastrointestinal cancers were as 20% esophageal, 55% gastric and 24% colorectal.

The median survival time was 18.7 months in total. The median survival time for esophageal, gastric and colorectal cancers was 9.32, 11.41 and 72 months respectively. The median survival time for esophageal cancer in term of sex; in females was 19.3 months and in males was 8 months; and for gastric cancer; in females was 12.88 months and in males was 10.97 months; and for colorectal cancer; in females was 72 months and in males was 74.20 months. Based on the results of life table, the one, three and five year survival rates were accordingly 45%, 36% and 27% in total. Besides, according to the type of gastrointestinal cancer, the one and three year survival rates were 28% and 9% for esophageal cancer and the one, three and five year survival rates were 31%, 26% and 14% for gastric cancer and 96%, 86% and 75% for colorectal cancer respectively. Demographic and cancer characteristics of patients with gastrointestinal cancers and their effects on survival rate were indicated in tables [1](#T1 T2){ref-type="table"}-[3](#T3){ref-type="table"}. Based on the univariate analysis using log-rank test, the variables of age, educational level, ethnicity, smoking, type of cancer, stage of disease and type of treatment had significant effects on survival. The significant results were not observed with the variables of sex ([Table 1](#T1){ref-type="table"}). Although this variable was not statistically significant but the median survival time was nearly more in females than males ([Figure 1](#F1){ref-type="fig"}).

###### 

Demographic characteristics of patients with gastrointestinal cancers and their effects on survival using log-rank test (univariate analysis)

  Variable                 Category     N (%)      p-value
  ------------------------ ------------ ---------- ---------------------------------------
  Age group                \< 62        66(45.2)   0.011[\*](#t1f1){ref-type="table-fn"}
  ≥ 62                     80(54.8)                
                                                   
  Sex                      Male         99(67.8)   0.461
  Female                   47(32.2)                
                                                   
  Income level             weak         60(46.2)   0.838
  Moderate                 16(12.3)                
  Well                     54(41.5)                
                                                   
  Educational level        illiterate   82(56.2)   0.002[\*](#t1f1){ref-type="table-fn"}
  Primary(school)          35(24)                  
  Secondary(high school)   11(7.5)                 
  University               13(8.9)                 
                                                   
  Ethnicity                Fars         47(32.2)   0.024[\*](#t1f1){ref-type="table-fn"}
  Tourk                    72(49.3)                
  Kord                     5(3.4)                  
  Lour                     3(2.1)                  
  Gilak                    10(6.8)                 
                                                   
  Smoking                  Non-smoker   89(61)     0.011[\*](#t1f1){ref-type="table-fn"}
  Smoker                   34(23.3)                

Significant at level of 0.05.

###### 

Cancer characteristics and their effects on survival using log-rank test (univariate analysis)

  Variable                                               Category    N(%)       p-value
  ------------------------------------------------------ ----------- ---------- ---------------------------------------
  Type of cancer                                         Esophagus   30(20.5)   0.001[\*](#t2f1){ref-type="table-fn"}
  Gastric                                                81(55.5)               
  Colorectal                                             35(24)                 
                                                                                
  Type of treatment                                      Surgery     48(32.9)   0.006[\*](#t2f1){ref-type="table-fn"}
  RT &/or CT^[a](#t2f2){ref-type="table-fn"}^            27(18.5)               
  Combination therapy^[b](#t2f3){ref-type="table-fn"}^   59(40.4)               

Significant at level of 0.05.

RT: radiotherapy, CT: chemotherapy.

Surgery and adjuvant or neoadjuvanttherapy.

###### 

Cancer characteristics and their effects on survival rate by type of gastrointestinal cancer using log-rank test (univariate analysis)

  variable                                           category                                         Esophageal cancer   Gastric cancer   Colorectal cancer                         
  -------------------------------------------------- ------------------------------------------------ ------------------- ---------------- ------------------- ---------- ---------- -------
  Location of Tumor                                  Proximal                                         2(6.7)              0.941            28(34.6)            0.082      \-         0.635
  Middle                                             12(40)                                                               13(16)                               \-                    
  Distal                                             16(53.3)                                                             37(45.7)                             \-                    
  Holestomach                                        \-                                                                   3(3.7)                               \-                    
  Colon                                              \-                                                                   \-                                   18(51.4)              
  Rectum                                             \-                                                                   \-                                   17(48.6)              
  Morphology                                         Intestinal Ac^[a](#t3f1){ref-type="table-fn"}^   5(16.7)             0.366            64(79)              0.478      30(85.7)   0.143
  Diffuse Ac                                         \-                                                                   8(9.9)                               \-                    
  Mucinproducing Ac                                  3(10)                                                                9(11.1)                              5(14.3)               
  KeratinizingScc^[b](#t3f2){ref-type="table-fn"}^   17(56.7)                                                             \-                                   \-                    
  Non KeratinizingScc                                5(16.7)                                                              \-                                   \-                    
  Stage of disease                                   Local                                            13(43.3)            0.131            26(32.1)            0.0003     13(37.1)   0.292
  Regional                                           6(20)                                                                33(40.7)                             16(45.7)              
  Metastatic                                         11(36.7)                                                             22(27.2)                             6(17.1)               

Adenocarcinoma.

Squamous cell carcinoma.

![Kaplan-Meier curve of patients by sex](GJHS-8-256-g001){#F1}

Also, based on the univariate analysis on cancer characteristics, significant results wasnot observed with the variables of tumor location (in esophageal cancer including proximal/middle/distal; in gastric cancer including proximal/middle/distal/whole stomach; in colorectal cancer including colon/rectum) and morphology (in esophageal cancer including intestinal Adenocarcinoma(AC)/Mucin producing AC/keratinizing Squamous cell carcinoma (SCC)/not keratinizing SCC; in gastric cancer including intestinal AC/diffuse AC/Mucin producing AC; in colorectal cancer including intestinal AC/Mucin producing AC). In case of the stage of disease, significant survival difference was only observed for gastric cancerthat is probability due to a large sample size for gastric cancer (p\<005); for this reason, this variable did not consider in multivariate analysis (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

Besides, the multivariate analysis using forward Cox regression model was made after assessing the assumption of constant relative hazard during the time by using log-log plot. Based on the results of [Table 4](#T4){ref-type="table"}, the variables of cancer type and type of treatment were considered to be effective significant factors on survival of patients. The hazard ratio(HR) for esophageal and gastric cancers were about 12.39 and 11.65 times more than that seen in colorectal cancer accordingly (p\<005). In fact, patients with esophageal cancer are exposed at a higher risk of death. The survival curve of each gastrointestinal cancer is given in [figure (2)](#F2){ref-type="fig"} separately.

###### 

Results of fitting the cox regression model (multivariate analysis)

  Variable                                               category    coefficient   Standard Error                            p-value                                   HR^[\*](#t4f1){ref-type="table-fn"}^
  ------------------------------------------------------ ----------- ------------- ----------------------------------------- ----------------------------------------- --------------------------------------
  Type of cancer                                         Esophagus   2.52          0.649                                     0.001[\*\*](#t4f2){ref-type="table-fn"}   12.39
  Gastric                                                2.46        0.607         0.001[\*\*](#t4f2){ref-type="table-fn"}   11.65                                     
  Colorectal                                             \-          \-            \-                                        Reference                                 
                                                                                                                                                                       
  Type of treatment                                      Surgery     0.175         0.334                                     0.600                                     1.192
  RT &/or CT^[a](#t4f3){ref-type="table-fn"}^            0.739       0.317         0.020[\*\*](#t4f2){ref-type="table-fn"}   2.094                                     
  Combination therapy^[b](#t4f4){ref-type="table-fn"}^   \-          \-            \-                                        Reference                                 

Hazard Ratio.

Significant at level of 0.05.

RT: radiotherapy, CT: chemotherapy.

Surgery and adjuvant or neoadjuvanttherapy.

![Kaplan-Meier curve of patients by type of gastrointestinal cancer.](GJHS-8-256-g002){#F2}

Also, the hazard ratio in patients underwent RT &/or CT were 2 folds greater than that seen in patients under combination therapy (p\<005) but the hazard ratio in patients who underwent surgery only was 19% more than those with combination therapy (p\<005). In other word, RT &/or CT showed an increased risk of death as compared to surgery only or those with combination therapy (Surgery and adjuvant or neoadjuvant therapy) ([Figure 3](#F3){ref-type="fig"}).

![Kaplan-Meier curve of patients by type of treatment.](GJHS-8-256-g003){#F3}

4. Discussion {#sec1-4}
=============

This study was aimed to determine the effective factors on survival of gastrointestinal cancers among Iranian population during 5 years of follow up. Although in most of the recent studies survival of upper and lower gastrointestinal cancer is investigated separately but the aim of this study is to determine the effective factors on survival of gastrointestinal cancers combined. In our study based on the results of life table; the survival rates for gastric cancer were more or close to the survival rates of other studies with overall 5-years survival of 16.2% ([@ref3]) and 18% ([@ref24]) and 1,3,5 years survival rates of 41%, 13%, 5.4% respectively ([@ref41]). In our study, the survival rates for colorectal cancer were approximately higher than those reported in most recent studies with 1,3,5 years survival rates of 84%, 54%, 41% ([@ref27]), and survival rates of 72%, 54%, 47% ([@ref23]), and overall 5-years survival of 38.6% ([@ref19]). This difference in survival of colorectal cancer in our study is perhaps due to an earlier diagnosis in our open access endoscopy center and is also because of improvement in their treatment due to the advance in therapeutic protocols including the neoadjuvant one.

In our study, the one and three years survival rates for esophageal cancer were lower than those reported with 55%, 18% in a study by [@ref25], and as 23%, 15% in a study by [@ref11], and as 51.3%, 20.1% in a study by [@ref18], and as 49%, 24% in a study by [@ref41]. This difference may be due to the low sample size of esophageal cancer patients in our study.

The results of present study based on univariate analysis using log rank test showed that, the variables of age, educational level, ethnicity, smoking, type of cancer and type of treatment had a significant survival differences but sex, location of tumor and morphology has not been indicated significant in survival differences. Although in our study the variable of sex did not have a significant effect on survival but the survival rate of females has been more than of males. Some Studies confirm the result of our study ([@ref11]; [@ref5]; [@ref22]; [@ref41]). Besides, in the evaluation of survival of patients according to the type of gastrointestinal cancers, our result showed that in the cancers of esophagus and stomach, females have had a better survival; although the survival rate between the both sexes have been almost alike in colorectal cancer. In most of studies, females had better survival in total ([@ref3], [@ref2]; [@ref10]). In most of studies a significant relation has been found between variable of age and survival rate as patients younger than 65 years had a better survival ([@ref23]; [@ref44]). In another study, the covariate of age had inverse relation with survival of patients with esophageal cancer ([@ref36]). In our study, patients younger than 62 years suffering from gastrointestinal cancers (esophagus, stomach and colorectal cancer) had longer survival. In our study based on the univariate analysis, university degree, non-smoking and receiving surgery and combination therapies implied on better survival. In a study, the variable of smoking had inverse effect on survival of patients with upper gastrointestinal cancer ([@ref39]) which was similar to our findings.

In the concomitant study of variables, based on the results of multivariate analysis using Cox model, variables of type of cancer and type of treatment had statistically significant effect on the patients' survival which is also mentioned as the effective factors on survival in univeriate analysis in present study.

Our results showed that patients with esophageal cancer were exposed at a highest risk of death. In a study on survival of patients with upper gastrointestinal cancers among Iran and in British Columbia (multi-ethnic population), Canada, result of multivariate analysis has proposed that the survival of patients suffering from gastric cancer has been better than that of esophageal cancer ([@ref2]); while in another study in Iran, patients with esophageal cancer had a slightly better survival which could have been due to a wider Screening program of this cancer in north-west of this country ([@ref33]). Besides, in a study of patients' survival with and without metastatic stage, it is reported that patients with colorectal cancer have a longer life than patients with gastric cancer ([@ref26]). These results confirm our findings which are briefly indicated in [Table 5](#T5){ref-type="table"}.

###### 

Results of other studies by type of gastrointestinal cancers

  study                             Type of gastrointestinal cancer   \%     Mean age   Male (%)   Female (%)   Median survival time(month)   HR          Effective factors on survival using Cox model
  --------------------------------- --------------------------------- ------ ---------- ---------- ------------ ----------------------------- ----------- -----------------------------------------------------------------
  Moghimi-Dehkordi et al. in 2009   Gastric cancer                    60     55.9       61         29           42.46                         2.25        Distant metastasis, grade of tumor
  Colorectal cancer                 39.8                              71     38.8       104.9      1.92                                                   
  Samadi et al. in 2007             Gastric cancer                    66.4   64         77.8       22.2         11.8                          Reference   Type of treatment, smoking status
  Esophageal cancer                 33.5                              53.9   46.1       12.1       0.86                                                   
  Bashash et al. in 2011            Gastric cancer                    20     67         78.9       21.1         20                            0.64        Ethnicity, type of treatment, tumor location and histology, sex
  Esophageal cancer                 60                                       71.4       28.6       7            1.13                                      

The choice of treatment type (with or without surgery) has solely been based on staging and probability of response to treatment and informed consent of patients. In another result of multivariate analysis in present study, patients who underwent RT &/or CT were exposed at a higher risk of death, which may be related to a higher stage of their disease due to a delayed diagnosis. In study on patients suffering from upper gastrointestinal cancers, results of multivariate analysis showed that patients who underwent surgery had 51% lower mortality than those who received non-surgical treatment ([@ref33]). In a study by [@ref44] using Cox model, gastric cancer patients who underwent surgery (HR=0.6) had better survival than those who underwent radiotherapy (HR=0.8). In a study by [@ref36] using Cox model, esophageal cancer patients who underwent surgery (HR=0.81) had better survival than those who underwent chemo radiotherapy (HR=1.48). In another study on upper gastrointestinal cancers, results of univariate analysis showed that esophageal cancer patients who received surgery had more survival than those who received chemotherapy or radiotherapy (median survival time of 12 v.s 5), also gastric cancer patients who received surgery had more survival than those who received chemotherapy or radiotherapy (median survival time of 12 v.s 9 and 7 respectively) ([@ref41]). In a study on esophageal cancer in Iran, patients who received chemotherapy or chemo radiotherapy along with Surgery (HR=0.19) had better survival than patients who received these treatments without Surgery such as only chemotherapy (HR= 0.79) or only radiotherapy (HR=0.63) ([@ref1]). In another study, esophageal cancer patients with only surgical treatment were almost at higher risk of death than those who did not have surgery (HR= 1.14) ([@ref25]). Based on other results, surgery and/or combination therapy such as chemo radiotherapy ([@ref18]) followed by surgery ([@ref37]) or complete surgical resection and adjuvant chemotherapy ([@ref19]) are Related to decrease the risk of death in gastrointestinal cancer. Results of these studies confirm our findings.

5. Conclusion {#sec1-5}
=============

This study has attempted to determine the effective factors on survival of patients with gastrointestinal cancer. Results of this study indicate that the type of cancer and type of treatment are considered as potential risk factors on survival of patients. In the other word, patients with esophageal cancer undergoing RT &/or CT are exposed to a higher risk of death. Our findings also indicate that surgery and/or combination therapy are associated with the better survival in patients with gastrointestinal cancer. Definitely, the best therapeutic response for patients is surgical operation, and in practice also surgical operation with acceptance of its higher risk is probably a practical recommendation. Therefore our findings can provide beneficial information to extend the cancer screening programs in order to achieve an earlier diagnosis to reduce mortality and its related risk factors.
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